AcquisitionsMay 20, 2026, 07:39 AM
Jupiter Neurosciences to acquire US rights for MDMA-based ALA-002
AI Summary
Jupiter Neurosciences, Inc. announced a term sheet to acquire exclusive, perpetual United States licensing rights to ALA-002, a lead drug candidate from PharmAla Biotech Holdings Inc. The deal involves an upfront payment of $3.33 million, consisting of $1.50 million in cash and $1.83 million in JUNS common stock, plus future milestone payments and royalties. This strategic move positions Jupiter in the rapidly growing psychedelic therapeutics market, bolstered by President Trump's recent Executive Order to accelerate psychedelic medicine.
Key Highlights
- Jupiter Neurosciences to acquire exclusive US licensing rights for ALA-002 from PharmAla Biotech.
- Upfront payment of $3.33 million, comprising $1.50 million cash and $1.83 million in JUNS common stock.
- JUNS shares issued will be subject to a 120-day lock-up period.
- Additional development milestone payments and single-digit royalties will be paid to PharmAla.
- Jupiter deposited $600,000 into escrow, creditable against the upfront cash consideration.
- ALA-002 is a patented, non-racemic MDMA formulation, recognized by the FDA as a Novel Chemical Entity.
- The psychedelic therapeutics market is projected to reach $6B-$15B annually by early-to-mid 2030s.
- President Trump's Executive Order accelerates access to investigational psychedelic therapies.
Price Impact
More from JUNS